Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families

Acta Anaesthesiologica Belgica

Volumn 58, Issue 2, 2007, Pages 113-118

  Heytens, L ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Genetic diagnosis; In vitro contracture test; Malignant hyperthermia; Ryanodine receptor

Indexed keywords

RYANODINE RECEPTOR 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE MUTATION; GENETIC COUNSELING; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; SEQUENCE ANALYSIS;

AMINO ACID SUBSTITUTION; BELGIUM; DNA; DNA PRIMERS; EXONS; GENOTYPE; HUMANS; MALIGNANT HYPERTHERMIA; MOLECULAR BIOLOGY; MUTATION; PEDIGREE; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 34447324122     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Galli L., Orrico A., Lorenzini S., Censini S., Falciani M., Covacci A., Tegazzin V., Sorentino V., Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia, HUM. MUTAT., 27 (8), 830-834, 2006.
2. Girard T., Urwyler A., Censier K., Mueller C. R., Zorzato F., Treves S., Genotype-phenotype comparison of the Swiss malignant hyperthermia population, HUM. MUTAT., 18 (4) : 357-358, 2001.
3. Ibarra M. C. A., Wu S., Murayama K., Minami N., Ichihara Y., Kikuchi H., Noguchi S., Hayashi Y. K., Ochiai R., Nishino I., Malignant hyperthermia in Japan : mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing, ANESTHESIOLOGY, 104 (6), 1146-1154, 2006.
4. Klingler W., Lehmann-Horn F., Jurkat-Rott K., Complications of anesthesia in neuromuscular disorders, NEUROMUSC. DISORDERS, 15, 195-206, 2005.
5. Monnier N., Kozak-Ribbens G., Krivosic-horber R., Nivoche Y., Qi D., Kraev N., Loke J., Sharma P., Tegazzin V., Figarella-Branger D., et al., Correlations between genotype and pharmacological histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility, HUM. MUTAT., 26 (5) : 413-425, 2005.
6. Ording H., In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group : results of testing patients surviving fulminant MH and unrelated low-risk subjects, ACTA ANAESTHESIOL. SCAND., 41, 955-966, 1997.
7. Robinson R. L., Anetseder M. J., Brancadoro V., Van Broeckhoven C., Carsane A., Censier K., Fortunate G., Girard T., Heytens L., Hopkins P. M., et al., Recent advances in the diagnosis of malignant hyperthermia susceptibility : how confident can we be of genetic testing?, EUR. J. HUM. GENET., 11, 342-348, 2003.
8. Sambuughin N., Holley N., Muldoon S., Brandom B. W., de Bantel A. M., Tobin J. R., Nelson T. E., Goldfarb L. G., Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north American population, ANESTHESIOLOGY, 102, 515-521, 2005.
9. Sambuughin N., Sei Y., Gallagher K. L., Wyre H. W., Madsen D., Nelson T. E., Fletcher J. R., Rosenberg H., Muldoon S. M., North American malignant hyperthermia population : screening of the ryanodine receptor gene and identification of novel mutations, ANESTHESIOLOGY, 95 (3), 594-599, 2001.
10. Urwyler A., Deufel T., McCarthy T., West S., Guidelines for the molecular detection of susceptibility to malignant hyperthermia, BR. J. ANAESTH., 86, 283-287, 2001.
11. Weckx S., Del-Favero J., Rademakers R., Claes L., Cruts M., De jonghe P., Van Broeckhoven C., De Rijk P., Novo SNP, a novel computational tool for sequence variation discovery, GENOME RES., 15 (3), 436-442, 2005.
12. Weckx S., De Rijk P., Van Broeckhoven C., Del-Favero J., SNPbox : web-based high-throughput primer design from gene to genome, NUCLEIC ACIDS RES., 32 (Web Server issue) : W170-172, 2004.